NCT04777643 is a EARLY_PHASE1 clinical trial of Cannabidiol in CBD, sponsored by Yale University.

Who is sponsoring NCT04777643?

NCT04777643 is sponsored by Yale University.

What drugs are being tested in NCT04777643?

Interventions in NCT04777643: Cannabidiol, Placebo.

What condition does NCT04777643 study?

NCT04777643 studies CBD, Neural Responses.

Is NCT04777643 still recruiting?

NCT04777643 is currently completed. Last updated 21 December 2023.

Last reviewed 2023-12-21 · How we verify

NCT04777643

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sex Differences in Neural Response to Cannabidiol

Completed EARLY_PHASE1 Last updated 21 December 2023

What this trial tests

EARLY_PHASE1 trial testing Cannabidiol in CBD in 19 participants. Completed in 27 April 2023.

Timeline

7 June 2022

Primary endpoint
27 April 2023

27 April 2023

Quick facts

Lead sponsor	Yale University
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Enrollment	19
Start date	7 June 2022
Primary completion	27 April 2023
Estimated completion	27 April 2023
Sites	1 location across United States

Drugs / interventions tested

Cannabidiol (CANNABIDIOL) — full drug profile →
Placebo

Conditions studied

CBD — all drugs for CBD →
Neural Responses — all drugs for Neural Responses →

Sponsor

Yale University

Who can join

Adults 18 to 65, female only, with CBD or Neural Responses. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, within-subjects, cross-over design to assess neural changes following a single dose of cannabidiol (CBD) (600mg) versus placebo among healthy female volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cannabidiol

Trials testing the same drug.

NCT07527338 — Mechanisms of Cannabidiol and Sleep in the Context of Alcohol Use · Phase 2, PHASE3 · not yet recruiting
NCT07278505 — Study of Cannabidiol and Neuroimaging on Stress · Phase 1, PHASE2 · recruiting
NCT06731894 — Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors · Phase 2 · recruiting
NCT06381180 — Warrior CARE: Cannabis Behavioral Health · Phase 1, PHASE2 · not yet recruiting
NCT06854783 — Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers · Phase 1 · completed

Other recruiting trials for CBD

Currently open trials in the same condition.

NCT07001930 — Effects of Cannabidiol on Stress and Nicotine Withdrawal · Phase 1 · recruiting
NCT07069478 — Cannabidiol (CBD) and Stress Response: Psychobiological Mechanisms · NA · recruiting
NCT05956834 — A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes · active not recruiting
NCT04482244 — RCT of CBD for Anxiety in Advanced Breast Cancer · Phase 2 · active not recruiting
NCT04778644 — Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task · Phase 1, PHASE2 · active not recruiting

Other Yale University trials

Trials by the same sponsor.

NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04777643 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yale University
Last refreshed: 21 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04777643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing